Cheap malaria drug is going to wrong people, says charityBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7157 (Published 23 October 2012) Cite this as: BMJ 2012;345:e7157
- Anne Gulland
The Global Fund to Fight Aids, Tuberculosis and Malaria is being urged to end a scheme aimed at providing cheap malaria treatment to poor countries because the people selling the drugs are not trained in malaria diagnosis.
The call has been made by the UK charity Oxfam in a damning critique of the affordable medicines facility—malaria (AMFm), which the Global Fund runs.1
The facility, which was launched in 2009 in eight pilot sites in seven countries in Asia and sub-Saharan Africa, aimed to expand access to artemisinin based combination therapy (ACT) to treat malaria.2 The Global Fund negotiated with drug manufacturers to reduce the price of the combination and to require that prices must be the same in the public and private sectors. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial